Enzalutamide continuation study for men with prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study looks at whether continuing enzalutamide, the same prostate cancer pill you’re already taking (or about to restart), can keep helping. It’s for people who previously joined an enzalutamide study and are doing well enough to stay on the same plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must already be taking enzalutamide for prostate cancer (or be assigned to restart it) in a sponsored Astellas or Medivation study
- Your cancer must not have progressed on your current enzalutamide study, and you must not have been stopped for study reasons
- You must be able to swallow enzalutamide capsules and follow all study visits and rules
- You must not join another interventional (hands-on) treatment study during this study
- If you or your female partner could become pregnant, you must use two forms of birth control—one highly effective—for the whole study and for a set time after
- You must not need new cancer medicines or investigational drugs other than enzalutamide (palliative radiation is allowed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
This study looks at how levels of common prostate cancer hormone treatments (abiraterone, apalutamide, darolutamide, or enzalutamide) stay in your blood over time. By checking drug levels, doctors hope to personalize dosing to make treatment safer and more effective.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
This Phase 2 trial tests whether giving testosterone first, then enzalutamide (a prostate cancer hormone-blocking pill), can slow or prevent worsening metastatic prostate cancer. It is designed for men whose cancer progressed despite ongoing hormone-suppression treatment.
This Phase 1 trial tests a new medicine (TVB-2640) combined with enzalutamide in men with prostate cancer that has spread and is no longer responding to hormone treatment. It aims to find a safe dose and see how well the treatment can work against the cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.